ReviewInternational journal of hematology2011
Novel therapies in MM: from the aspect of preclinical studies.
Review in International journal of hematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.The Journal of biological chemistry · 2013Trial
- CD44-downregulation in multiple myeloma inhibits cytoskeleton rearrangement through actin depolymerization.Clinical and experimental medicine · 2025Article
- MiR-19b and miR-20a suppress apoptosis, promote proliferation and induce tumorigenicity of multiple myeloma cells by targeting PTEN.Cancer biomarkers : section A of Disease markers · 2019Article
- Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma.International journal of hematology · 2016Article
- Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.The Journal of clinical investigation · 2015Article
- Article
- MicroRNA-21 and multiple myeloma: small molecule and big function.Medical oncology (Northwood, London, England) · 2014Review
- Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.Molecular cancer therapeutics · 2013Article
- Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Article
- Current approaches for the treatment of multiple myeloma.International journal of hematology · 2013Review
- Multiple myeloma-initiating cells.International journal of hematology · 2013Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the last decade, thalidomide, lenalidomide, and bortezomib have been approved by the US Food and Drug Administration for the treatment of MM; however, MM remains incurable. The development and progression of multiple myeloma (MM) is a complex multi-step process involving genetic abnormalities in tumor cells at both early and late stages. Moreover, soluble factors and cell-cell contact within the tumor bone marrow (BM) microenvironment promotes MM cell growth, survival, and drug resistance. A number of novel agents targeting both tumor cells and growth factors in the BM milieu have been developed. Currently they are under evaluation in preclinical studies, as single agents and/or in combination, to improve outcome of MM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.